#1 Clinical Trials Search in Europe

Benralizumab

Benralizumab is an innovative medication being studied in clinical trials for various eosinophilic conditions, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and chronic rhinosinusitis. This article explores the use of benralizumab in clinical trials, its potential benefits, and its impact on patients with eosinophil-related disorders.

Table of Contents

What is Benralizumab?

Benralizumab is a medication used to treat certain types of severe asthma and other eosinophil-related conditions. It’s also known by the brand name Fasenra[2]. Benralizumab belongs to a class of drugs called monoclonal antibodies, which are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses[1].

Conditions Treated by Benralizumab

Benralizumab is primarily used to treat:

  • Severe Eosinophilic Asthma: This is a type of asthma characterized by high levels of eosinophils (a type of white blood cell) in the blood and airways[2].
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA): A rare blood vessel disease that causes inflammation in the blood vessels and can affect various organs[3].
  • Eosinophilic Chronic Rhinosinusitis: A condition causing inflammation of the nose and sinuses[4].

Research is also ongoing to explore its potential in treating other conditions, such as exercise-induced asthma and certain skin side effects caused by cancer therapies[5][6].

How Benralizumab Works

Benralizumab works by targeting and blocking a specific protein called the interleukin-5 receptor alpha (IL-5Rα) found on the surface of eosinophils. By doing this, it reduces the number of eosinophils in the blood and tissues, which helps to decrease inflammation in the airways and other affected areas[1].

This reduction in eosinophils can lead to several benefits for patients with severe eosinophilic asthma, including:

  • Fewer asthma exacerbations (sudden worsening of asthma symptoms)
  • Improved lung function
  • Better quality of life
  • Reduced need for oral corticosteroids (a type of anti-inflammatory medication)[2]

How Benralizumab is Administered

Benralizumab is typically administered as a subcutaneous injection (an injection under the skin). The usual dosing schedule is:

  • 30 mg every 4 weeks for the first three doses
  • Then 30 mg every 8 weeks thereafter[5]

The injections are usually given by a healthcare provider in a clinical setting[6].

Effectiveness of Benralizumab

Clinical trials have shown that benralizumab can be effective in managing severe eosinophilic asthma. Some of the reported benefits include:

  • Significant decrease in asthma exacerbations
  • Improvement in lung function
  • Better quality of life for patients
  • Reduction in the use of oral corticosteroids[7]

It’s important to note that the effectiveness can vary from person to person, and it may take several weeks or months to see the full benefits of the treatment.

Potential Side Effects

Like all medications, benralizumab can cause side effects. Common side effects may include:

  • Headache
  • Sore throat
  • Fever
  • Reactions at the injection site (such as pain, redness, or swelling)[2]

More serious side effects are rare but can include allergic reactions. It’s important to discuss potential side effects with your healthcare provider before starting treatment.

Ongoing Research and Future Applications

Researchers are continually studying benralizumab to understand its full potential. Some areas of ongoing research include:

  • Its effect on exercise-induced asthma[5]
  • Its potential use in treating skin side effects caused by cancer therapies[6]
  • Its impact on dendritic cells (a type of immune cell) in patients with severe eosinophilic asthma[8]
  • Its effectiveness in children with eosinophilic diseases[3]

These ongoing studies may lead to new applications for benralizumab in the future, potentially benefiting more patients with eosinophil-related conditions.

Aspect Details
Drug Name Benralizumab (also known as FASENRA)
Mechanism of Action Targets interleukin-5 receptor alpha (IL-5Rα) on eosinophils
Administration Subcutaneous injection, typically 30 mg
Dosing Schedule Every 4 weeks for first 3 doses, then every 8 weeks
Conditions Studied Severe eosinophilic asthma, EGPA, eosinophilic chronic rhinosinusitis
Primary Outcomes Reduction in exacerbations, improvement in lung function, reduction in oral corticosteroid use
Secondary Outcomes Changes in eosinophil counts, quality of life measures, asthma control scores
Safety Monitoring Adverse events, serious adverse events, changes in vital signs and laboratory values
Trial Phases Phase 2, Phase 3, and Phase 4 studies
Patient Populations Adults and children with eosinophilic conditions

FAQ

  • What is benralizumab and how does it work? Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha (IL-5Rα) on eosinophils. It works by blocking the specific protein interleukin-5, which leads to a reduction in eosinophil levels in the blood and tissues.
  • What conditions is benralizumab being studied for in clinical trials? Benralizumab is being investigated for various eosinophilic conditions, including severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic chronic rhinosinusitis, and eosinophil-related cutaneous adverse events in cancer patients.
  • How is benralizumab administered in clinical trials? In most clinical trials, benralizumab is administered as a subcutaneous injection, typically 30 mg every 4 weeks for the first three doses, followed by every 8 weeks thereafter. The exact dosing schedule may vary depending on the specific trial.
  • What are some potential benefits of benralizumab treatment? Clinical trials suggest that benralizumab may help reduce asthma exacerbations, improve lung function, allow for reduction in oral corticosteroid use, and potentially improve quality of life for patients with eosinophilic conditions.
  • Are there any side effects associated with benralizumab in clinical trials? While specific side effects can vary, clinical trials are designed to monitor the safety and tolerability of benralizumab. Common side effects may include injection site reactions. Serious adverse events are closely monitored and reported during the trials.

Ongoing Clinical Trials on Benralizumab

  • Study on the Effectiveness and Safety of Benralizumab with Budesonide and Formoterol in Patients with Eosinophilic Asthma Uncontrolled by Standard Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Bulgaria France Germany Ireland Italy Norway +1

  • Study on Benralizumab for Patients with Severe Asthma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Benralizumab for Children with Severe Eosinophilic Asthma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study on Benralizumab and Mometasone Furoate for Patients with Severe Eosinophilic Chronic Rhinosinusitis with Nasal Polyps and Asthma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Hungary Italy Poland

  • Study on the Effects of Benralizumab on Lung Function in Patients with Severe Eosinophilic Asthma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Sweden

  • Study on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy

  • Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Finland France Germany Ireland Italy +6

  • Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES)

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark France Germany Italy +3

  • Study on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Germany +7

Glossary

  • Eosinophil: A type of white blood cell that plays a role in the immune system and is involved in allergic reactions and certain inflammatory conditions.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body, such as certain cells or proteins, and is used in the treatment of various diseases.
  • Interleukin-5 (IL-5): A protein that plays a crucial role in the production and activation of eosinophils.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Exacerbation: A worsening of symptoms or an increase in the severity of a disease.
  • Eosinophilic granulomatosis with polyangiitis (EGPA): A rare autoimmune condition characterized by inflammation of blood vessels and the presence of high levels of eosinophils.
  • Chronic rhinosinusitis: Long-term inflammation of the nasal passages and sinuses.
  • Forced Expiratory Volume in 1 second (FEV1): A measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Oral corticosteroids: A type of anti-inflammatory medication taken by mouth to treat various conditions, including severe asthma and other inflammatory disorders.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.eu/trial/study-on-benralizumab-for-patients-with-severe-asthma/
  2. https://clinicaltrials.gov/study/NCT06465485
  3. https://clinicaltrials.gov/study/NCT06512883
  4. https://clinicaltrials.gov/study/NCT02772419
  5. https://clinicaltrials.gov/study/NCT03327701
  6. https://clinicaltrials.gov/study/NCT04552288
  7. https://clinicaltrials.gov/study/NCT04102800
  8. https://clinicaltrials.gov/study/NCT03652376